The Janus Corner · Volume 16, Issue 3 (2026) · pp. 157–158
The use of Ozempic® and Similar GLP-1 Agonists Significantly Decrease the Risk of Developing Breast Cancer in Women
Ian Edwin Cock1
- 1School of Environment and Science, Nathan Campus, Griffith University, 170 Kessels Rd, Nathan, Brisbane, Queensland, AUSTRALIA.
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1) are well known for their effective treatment of Diabetes mellitus (DM), their positive effects on renal and cardiovascular function, as well as for promoting weight loss.1 A recent study reported that they also significantly reduce the incidence of breast cancer in women.2 That study examined the medical records of nearly 220,000 women aged 45 to 80 years old who underwent breast imaging and analysed the rates of breast cancer detection. Interestingly, a significantly lower incidence of breast cancer was evident in women who used GLP-1 agonists compared to women not exposed to this treatment. The findings were independent of age, race and ethnicity, body mass index (BMI) and medical history of DM. Whilst this study is encouraging, directed clinical trials and determination of the protective mechanism are required to fully evaluate the potential of GLP-1 agonists as breast cancer preventative agents.
Keywords: The Janus Corner
The full text of this article, with its figures and tables, is its PDF, shown below. Open the PDF in a new tab.
